mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.

MLA

Schnitzbauer, Andreas A., et al. “MTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.” Annals of Surgery, vol. 272, no. 5, Nov. 2020, pp. 855–62. EBSCOhost, https://doi.org/10.1097/SLA.0000000000004280.

APA

Schnitzbauer, A. A., Filmann, N., Adam, R., Bachellier, P., Bechstein, W. O., Becker, T., Bhoori, S., Bilbao, I., Brockmann, J., Burra, P., Chazoullières, O., Cillo, U., Colledan, M., Duvoux, C., Ganten, T. M., Gugenheim, J., Heise, M., van Hoek, B., Jamieson, N., … Geissler, E. K. (2020). mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Annals of Surgery, 272(5), 855–862. https://doi.org/10.1097/SLA.0000000000004280

Chicago

Schnitzbauer, Andreas A, Natalie Filmann, René Adam, Philippe Bachellier, Wolf O Bechstein, Thomas Becker, Sherrie Bhoori, et al. 2020. “MTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.” Annals of Surgery 272 (5): 855–62. doi:10.1097/SLA.0000000000004280.